NCT03033914 - A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Hodgkin Lymphoma

Interventions

DRUG

doxorubicin

Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

DRUG

Bleomycin

Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

DRUG

vinblastine

Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

DRUG

dacarbazine

Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

Nivolumab

nivolumab 240mg q14 days

Trial Locations (10)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering Commack, Commack

Karmanos Cancer Institute, Detroit

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Hackensack Meridian Health, Hackensack

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale

BC Cancer (Data Collection Only), Vancouver